Addleshaw Goddard advises Hikma Pharmaceuticals on Ethiopian joint venture
Addleshaw Goddard has advised Hikma Pharmaceuticals plc on a 50–50 joint venture with Sheikh Mohammed Hussein Al Amoudi’s MIDROC Group.
The joint venture, called HikmaCure, establishes a presence for Hikma in the Ethiopian pharmaceutical market. Hikma and MIDROC will invest in HikmaCure in equal proportions and have committed to provide up to $22.3m (£13.8m) each in cash.
The Addleshaw Goddard team was led by corporate finance partner Chris Taylor with support from managing associate Simon Wood.
This is the third corporate transaction Addleshaw Goddard has advised on in Ethiopia in the last two years.
News from Addleshaw Goddard
News from The Lawyer
Briefings from Addleshaw Goddard
The Law Commission is conducting a limited consultation on the first available draft clauses from its proposed Insurance Contracts Bill.
InCredit March 2014 — mortgages: Mortgage Credit Directive text published in OJEU; FCA publishes findings to MCOB survey; and more
The text of the Mortgage Credit Directive (MCD) (2014/17/EU) has been published in the Official Journal of the EU.
Analysis from The Lawyer
Could Slater & Gordon achieve its stated aim of becoming a top consumer brand by acquiring Pannone?
The past five years have not been easy for Addleshaw Goddard. The firm’s revenue fell 7 per cent from £173.1m to £161.9m between 2008/09 and 2010/11 and despite finances looking up in 2011/12, when Addleshaws reported a 30 per cent increase in net profit, it has shown no notable compound growth in turnover since 2007/08.